Drug Therapy for Generalized Anxiety Disorder Among the Elderly

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

177 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Antidepressant Non-Response in Late-Life Depression

NCT01931202

Major Depressive Disorder

COMPLETED NA

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

NCT02411123

Depression Anxiety

COMPLETED NA

Treatment Response of Geriatric Depression

NCT00754936

Depression

COMPLETED NA

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

NCT02818751

Anxiety

COMPLETED NA

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder

NCT00252343

Anxiety Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GAD is a serious public health issue; particularly among the elderly, prevalence of the condition is high, and functional burden on those with the illness is significant. GAD is associated with irregular levels of neurotransmitters, chemicals that carry messages across nerve endings. Serotonin is a neurotransmitter that helps regulate mood and emotions; increased levels of serotonin have been shown to reduce anxiety. Standard treatment for GAD typically involves selective serotonin reuptake inhibitors (SSRIs), drugs that reduce serotonin re-entry into nerve cells. Escitalopram is an SSRI that is well tolerated and highly specific for the serotonin transporter (SERT). The primary aim of this study is to examine the efficacy of escitalopram in reducing anxiety symptoms among elderly GAD patients. Additional aims include examining the efficacy of escitalopram for improving function, quality of life, and neuropsychological functioning, and examining whether genetic variation in the SERT gene influences these participants' response to treatment.

Participants will be randomly assigned to receive either escitalopram or placebo for 12 weeks (there is also a 12 week open label extension in which all participants will receive escitalopram). Participants will have weekly/biweekly study visits; during these visits, participants will complete self-report questionnaires on functional ability and anxiety symptoms. Blood collection and cognitive testing through various tasks will also occur.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety Disorders Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escitalopram (1)

Escitalopram

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.

Placebo (2)

Placebo

Group Type PLACEBO_COMPARATOR

Escitalopram

Intervention Type DRUG

Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of at least moderately severe generalized anxiety disorder (GAD)

Exclusion Criteria

* Serious suicide risk or psychiatric instability that would affect study participation
* Dementia
* Substance abuse, such as alcoholism, within 6 months prior to study entry
* Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
* Unstable medical conditions that would preclude the use of escitalopram
* Use of certain psychotropics that can not be safely tapered or discontinued for at least 2 weeks prior to and during the study
* Use of neuroleptics that are absorbed over a prolonged period of time within 6 weeks prior to study entry

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No